| Drug NDC: | 63083-4005 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Bowel Pathogen Nosode 4005 |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Proprietary Name Base: | Bowel Pathogen Nosode |
| The base of the Brand/Proprietary name excluding its suffix. | |
| Proprietary Name Suffix: | 4005 |
| A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Bowel Pathogen Nosode |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Professional Complementary Health Formulas |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | AMOEBA PROTEUS - 30 [hp_X]/59mL ANCYLOSTOMA DUODENALE - 30 [hp_X]/59mL ASCARIS LUMBRICOIDES - 30 [hp_X]/59mL BLASTOCYSTIS HOMINIS - 30 [hp_X]/59mL CITROBACTER FREUNDII - 30 [hp_X]/59mL CLOSTRIDIUM BOTULINUM - 30 [hp_X]/59mL CLOSTRIDIUM PERFRINGENS - 30 [hp_X]/59mL CRYPTOSPORIDIUM HOMINIS - 30 [hp_X]/59mL DIPHTHERIAL RESPIRATORY PSEUDOMEMBRANE HUMAN - 30 [hp_X]/59mL ECHINOCOCCUS GRANULOSUS - 30 [hp_X]/59mL Load more... ENTEROCOCCUS FAECIUM - 30 [hp_X]/59mL ESCHERICHIA COLI - 30 [hp_X]/59mL GIARDIA LAMBLIA - 30 [hp_X]/59mL HELICOBACTER PYLORI - 30 [hp_X]/59mL NECATOR AMERICANUS - 30 [hp_X]/59mL PHERETIMA ASPERGILLUM - 30 [hp_X]/59mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 15 Aug, 1984 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 09 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Professional Complementary Health Formulas |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| UNII: | APR291GFYV 84H4A6227O 5694HE17ZQ 66KX72J4H6 16Z04YR6FK 0296055VE0 OVP6XX033E DKE8M34J72 50SG618FGN D0396L455U Load more... 34YYS7G16P 514B9K0L10 89IEJ09R73 U09W5JOL3Z 813Z1U3E4R 1842H27PGA |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 63083-4005-2 | 59 mL in 1 BOTTLE, DROPPER (63083-4005-2) | 15 Aug, 1985 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.